Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C4801002 - Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers
2023-505154-18-00Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2023
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of RSVpreF vaccine in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoints: Prompted local reactions, Prompted systemic events and 2 more. Started Oct 2023; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2023-505154-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505154-18-00.